Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology

BioArctic Sweden

Phone: [phone]

Jiang Millington, Corporate Communication and Social Media Director
E-mail: [e-mail]
Phone: [phone]

About Exidavnemab

Exidavnemab is a monoclonal antibody drug candidate that is designed to selectively bind and eliminate aggregated forms of alpha-synuclein such as oligomers and protofibrils and fibrillar forms, which participates in neurodegenerative disorders including Parkinson's disease. The goal is to develop a disease modifying treatment that stops or slow down the progression of Parkinson's disease. 

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and ALS. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partner Eisai in Alzheimer disease. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic's Class B share is listed on Nasdaq Stockholm Large Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/study-results-from-phase-1-studies-with-exidavnemab-published-in-the-journal-of-clinical-pharmacolog,c4028830

The following files are available for download:

https://mb.cision.com/Main/9978/4028830/2963458.pdf

Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology

 

View original content:https://www.prnewswire.co.uk/news-releases/study-results-from-phase-1-studies-with-exidavnemab-published-in-the-journal-of-clinical-pharmacology-302231302.html